Accepted answer
two weeks at 0.25 mg is 14 days at one dose level — and the arithmetic the question hides is that it also moves every dose above 0.25 mg back by 14 days. Whether that reduces nausea depends on which quantity it tracks. A symptom driven by the dose itself is unchanged by waiting: 0.25 mg is 0.25 mg on day 1 and on day 14. A symptom driven by the rate of change has 14 days of no change to settle in, which is the case the hold is actually made for. The distinction is testable on your own record: plot nausea against days-since-last-increase rather than against dose, and if the peaks line up with the increases the hold is doing something. Escalation schedules are set by a prescriber, and nothing here is medical advice.
This is the single most consequential controllable variable in the whole experience, and people routinely rush it.
Liraglutide titrates weekly rather than four-weekly because its half-life is about thirteen hours, so steady state is reached within days. The interval follows the pharmacokinetics in both cases.
Label titration ladders, structure only
| Agent | Start | Step interval | Maintenance range | Max studied |
|---|
| Semaglutide (weight management) | 0.25 mg/wk | 4 weeks | 1.7–2.4 mg/wk | 2.4 mg/wk |
| Semaglutide (T2DM) | 0.25 mg/wk | 4 weeks | 0.5–2.0 mg/wk | 2.0 mg/wk |
| Tirzepatide | 2.5 mg/wk | 4 weeks | 5–15 mg/wk | 15 mg/wk |
| Liraglutide (weight management) | 0.6 mg/day | 1 week | 3.0 mg/day | 3.0 mg/day |
| Oral semaglutide | 3 mg/day | 4 weeks | 7–14 mg/day | 50 mg/day (trial) |
Structure is identical across the class: small start, four-week steps, a defined maintenance range, a defined ceiling.
For an agent with a one-week half-life, steady state after a dose change is reached in about four to five weeks. Escalating at two weeks means escalating from a position you have not yet reached, and the resulting exposure is higher than the schedule intends.
Trial data show gastrointestinal adverse events concentrated in the escalation phase and declining at stable doses.
Nothing here is medical advice, and research-use compounds are not approved for human use.
Hold rather than escalate while symptoms are active. Always.
edited 28 Jul 2026 by Dr_Hanne_Solberg — tightened the wording; no substantive change
4Stepping back down being normal rather than a failure is worth saying out loud. – Dr_Tomas_Kral 5 months ago add a comment